The race to relief for peanut allergy sufferers pounded onward Tuesday, with Aimmune Therapeutics Inc. delivering endpoint-meeting outcomes from a pivotal phase III test of its oral immunotherapy, AR-101. The 499-participant trial found that about 67 percent of evaluable people treated with AR-101 tolerated a single highest dose of at least 600 mg of peanut protein with no more than mild symptoms vs. 4 percent of those given a placebo.